BridgeMD
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
EU CTIS ID: 2025-524367-20-00
What this study is testing
To study the safety and tolerability of 48 weeks of open-label KL1333 treatment in subjects previously treated with KL1333 or placebo in the FALCON study.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Completed the FALCON study (age 18 years or older) and, in the opinion of the investigator and Sponsor, has been compliant with the study requirements.
- 10. Female subjects must agree to not donate ova throughout the study period and for 36 days after the last dose of IMP administration, and male subjects must agree to not donate sperm throughout the study period and for 96 days after the last dose of IMP administration.
- 2. Willingness and ability to provide informed consent.
- 3. Willingness and ability to attend study appointments within the specified time windows.
- 4. Willingness and ability to complete electronic patient-reported outcomes (ePROs).
- 5. Concomitant medications likely to remain stable throughout participation in the study where clinically possible.
You likely can't join if
- 1. The subject is, in the investigator’s opinion, unlikely to comply with the protocol, e.g., due to cognitive impairment, or is unsuitable for any reason.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 10. Use of idebenone within 14 days prior to the first dose.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 11. Subjects have a history of unstable or severe pulmonary, immunological, oncological, hepatic disease, renal disease, or another medically significant illness other than PMD or takes medication that could, in the investigator’s opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 12. Female subjects with a positive pregnancy result at screening.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 13. A subject cannot participate if they received an investigational drug 30 days or 5 half lives prior to the screening visit (whichever is longer), or plans to use an investigational drug (other than the study intervention) during the study.
- 2. Any medical, psychiatric, laboratory, or other condition that may negatively affect the benefit-risk considerations of study participation or interfere with the interpretation of study results and, in the judgment of the investigator and/or the medical monitor, would make the subject inappropriate for entry into this study.
See the full eligibility criteria
Who can join
- 1. Completed the FALCON study (age 18 years or older) and, in the opinion of the investigator and Sponsor, has been compliant with the study requirements.
- 10. Female subjects must agree to not donate ova throughout the study period and for 36 days after the last dose of IMP administration, and male subjects must agree to not donate sperm throughout the study period and for 96 days after the last dose of IMP administration.
- 2. Willingness and ability to provide informed consent.
- 3. Willingness and ability to attend study appointments within the specified time windows.
- 4. Willingness and ability to complete electronic patient-reported outcomes (ePROs).
- 5. Concomitant medications likely to remain stable throughout participation in the study where clinically possible.
- 6. Willingness to continue suspension of idebenone during the study.
- 7. Female subject is not pregnant and at least one of the following conditions apply: a. Not a woman of childbearing potential (WOCBP) b. WOCBP must agree not to try and become pregnant and use a highly effective method of contraception from the time of informed consent through at least 36 days (~5 half-lives of KL1333 plus 30 days) after the last dose of IMP administration.
- 8. Male subjects with female partner(s) of childbearing potential must agree to use a male condom in addition to using highly effective contraception throughout the treatment period and for 96 days after the last dose of IMP administration. The requirement to use a male condom also applies to male subjects with a pregnant or breastfeeding partner.
- 9. Female subjects must agree not to breastfeed throughout the study period and for 36 days after the last dose of IMP administration.
What rules you out
- 1. The subject is, in the investigator’s opinion, unlikely to comply with the protocol, e.g., due to cognitive impairment, or is unsuitable for any reason.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 10. Use of idebenone within 14 days prior to the first dose.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 11. Subjects have a history of unstable or severe pulmonary, immunological, oncological, hepatic disease, renal disease, or another medically significant illness other than PMD or takes medication that could, in the investigator’s opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 12. Female subjects with a positive pregnancy result at screening.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 13. A subject cannot participate if they received an investigational drug 30 days or 5 half lives prior to the screening visit (whichever is longer), or plans to use an investigational drug (other than the study intervention) during the study.
- 2. Any medical, psychiatric, laboratory, or other condition that may negatively affect the benefit-risk considerations of study participation or interfere with the interpretation of study results and, in the judgment of the investigator and/or the medical monitor, would make the subject inappropriate for entry into this study.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 3. General fatigue or muscle weakness due to causes other than mitochondrial disease, in the opinion of the investigator.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 4. Significant cardiovascular disease (e.g., sustained or symptomatic arrhythmia, dilated heart chambers or reduced function, Mobitz II atrioventricular block or greater) OR abnormal ECG that is clinically significant, as determined by the investigator. Any QT interval corrected using Fridericia’s formula (QTcF) >450 msec for male subjects and >470 msec for female subjects is exclusionary. In the case of an exclusionary QTcF, the ECG can be repeated twice and the average of 3 QTcF intervals should be used to determine the QTcF eligibility.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 5. Recent history of unstable disease, inadequately controlled neurological manifestations or not recovered from stroke-like episodes including but not limited to: a. stroke-like episodes within the last 6 months b. more than 1 seizure/month within the last 6 months c. hospitalized for Status Epilepticus within the last 6 months d. more than 4 days of migraine episodes/month within the last 6 months
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 6. History of inflammatory bowel disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes. Gastroesophageal reflux disease diagnosed by objective endoscopic or radiographic means, and clinically symptomatic at any point over the last 6 months.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 7. The subject has 1 or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the screening visit, that are of potential risk to the subject’s safety, or the subject has, at the screening visit: a. estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation <30 mL/min/1.73 m2 b. a serum total bilirubin value >1.5 times the upper limit of the reference range unless elevation is related to Gilbert’s syndrome and the investigator can rule out any underlying liver dysfunction based on other tests, the subject has a Child-Pugh score ≤6, and after discussing the case with the medical monitor c. a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 times the upper limit of the reference range. Values between 2 and 3 times the upper limit of the reference range may be allowed if concomitant to elevation in creatine kinase as long as the investigator can rule out any underlying liver dysfunction based on other tests, the subject has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 8. The subject has, in the investigator’s opinion, severe ataxia, neuropathy, balance problems, or other medical conditions that would interfere the evaluation of the 30s STS.
- Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit: 9. Untreated or undertreated sleep apnea, in the opinion of the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.